The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBurford Capital Regulatory News (BUR)

Share Price Information for Burford Capital (BUR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,176.00
Bid: 1,170.00
Ask: 1,185.00
Change: -78.00 (-6.22%)
Spread: 15.00 (1.282%)
Open: 1,290.00
High: 1,290.00
Low: 1,148.00
Prev. Close: 1,254.00
BUR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re Successful Petersen Appeal Court Result

11 Jul 2018 07:00

RNS Number : 2340U
Burford Capital
11 July 2018
 

This announcement contains inside information.

 

11 July 2018

 

 

BURFORD CAPITAL UPDATES ON SUCCESSFUL PETERSEN APPEAL COURT RESULT

AND ALSO REPORTS ON FURTHER RELATED ACTIVITY

 

Burford Capital Limited ("Burford"), a leading global finance and investment management firm focused on law, announces that on 10 July 2018 the US Second Circuit Court of Appeals affirmed the trial court decision finding the Petersen claims against Argentina and YPF to be justiciable in the United States federal courts.

 

As a result, the case will now return to the trial court for substantive proceedings, although there is the possibility of the defendants seeking permission for a further review by the US Supreme Court, which is rarely granted. 

 

While we are pleased with this decision, it is important to emphasize that this decision relates purely to a preliminary jurisdictional question and does not foreshadow any particular result in the underlying litigation. 

 

Although the court's decision is a matter of public record upon its release (and is available here), Burford has issued this announcement as a matter of convenience. However, Burford does not intend to regularly issue such releases for other interlocutory steps in the proceedings, of which there are likely to be many before a final resolution.

 

Given the timing of the court's decision, Burford has not factored the impact of the court's decision into its investment valuation process for the period ended 30 June 2018, and will consider its impact, if any, in the investment valuation process for the period ending 31 December 2018. We discuss our valuation process further below.

 

Burford has also historically provided litigation financing in connection with similar claims advanced by Eton Park, the third-largest YPF shareholder, which at the relevant time held approximately 3% of YPF's equity. Although publicly disclosed, Burford's investment in the Eton Park matter has not historically been the subject of investor attention. However, Eton Park is now in the process of dissolving, and Burford thus agreed in June 2018 to take on a broader role in the Eton Park matter, comparable to its role in the Petersen claim, and made a $21 million advance payment to Eton Park in exchange for the right to receive a further 70% of Eton Park's proceeds from the YPF litigation less various fees and expenses.

 

In order to hold Burford's cash exposure to the YPF claims relatively constant, we decided to finance our payment to Eton Park by selling some further interests in our Petersen entitlement, and contemporaneously with closing the Eton Park transaction, we sold 3.75% of our entitlement for an effective cash price of $30 million, implying a valuation of $800 million for our original total Petersen entitlement, although we carry our Petersen investment at a lower carrying value than that for the reasons we have enunciated previously. When also considering prior secondary market sales, Burford now owns 71.25% of its original total entitlement.

 

Background to Burford's investment valuation process and its impact on reported earnings

 

Burford values transparency in its presentation of financial results and wants to be clear with investors about its approach to those results.

 

Most of Burford's income comes from its litigation finance business. Within that business, there are two principal sources of income for accounting purposes, realized gains on investments and unrealized gains on investments. (Realized and unrealized losses will naturally negatively affect income and the principles we set forth here apply equally to losses.) 

 

Realized gains are straightforward: they represent the amount of profit, net of the return of Burford's invested capital and any previously recognized unrealized gains, on an investment that has either resolved entirely or has been settled or adjudicated such that, in Burford's view, there is no longer litigation risk associated with the investment. (In the latter event, Burford may discount the anticipated profit in respect of an investment to account for any continuing uncertainty as to the recoverability of any amount.) Burford announces individual investment results that will produce realized gains separately from its financial results only when the individual gain is new information which may be material to Burford.

 

Unrealized gains are more complex: they represent the fair value of Burford's investment assets, as determined by Burford's board of directors in accordance with the requirements of the relevant IFRS standards, as at the end of the relevant financial reporting period. There is no active secondary market for litigation risk, and thus there is generally no market-based approach to assessing fair value; to the extent that a secondary market transaction does take place with respect to an investment, the implied value of that transaction is a key valuation input. In the absence of such a transaction, we are mindful that the outcome of each matter Burford finances is likely to be inherently uncertain, may take several years to conclude and is often difficult to predict with accuracy. Moreover, litigation matters frequently experience multiple significant shifts in sentiment during their evolution. Burford thus eschews fair values based solely on current sentiment, and focuses on objective events (such as court rulings or settlement offers) to ground its assessment of fair value.

 

Burford's board of directors assesses the fair value of Burford's investments after the close of each financial reporting period and therefore investors should not expect updates about potential changes in fair value during the course of any given reporting period. Following the close of each financial reporting period, Burford's board determines the fair values of investments after taking into account the views of management, the operation of the audit process and input from external experts (as it considers appropriate). Generally, that process does not conclude finally until shortly before the release of Burford's financial results for the relevant period.

 

Burford is pleased to be followed by a number of research analysts and we are grateful for their efforts to understand and explain our business. They perform a valuable role in assessing our operating performance, the evolution of the litigation finance market and interpreting other relevant industry developments. However, prospective investors and other market participants must appreciate that, due to the confidential, potentially privileged, long-term and uncertain nature of each investment asset, it is very difficult for research analysts to project accurately the likely investment income of the business. Any projections produced by research analysts are not produced on behalf of Burford and Burford takes no responsibility for such projections.

 

As a result, prospective investors and other market participants should not treat, and Burford does not intend to treat, the financial projections produced by research analysts as indicative of the market's expectations of Burford's future financial performance. We specifically eschew any obligation to correct estimates made by financial analysts or to inform the market should we come to believe that our actual performance will diverge from those estimates. This is, of course, different to the approach taken by most operating companies, in respect of which research analysts can produce relatively reliable estimates and the relevant company will advise the market if it expects to see performance materially different from the consensus of analyst forecasts. It is important that investors understand that Burford takes a different approach as a result of the different nature of its business.

 

 

The person responsible for arranging for the release of this announcement on behalf of the Company is Elizabeth O'Connell, Chief Financial Officer.

 

 

For further information, please contact:

 

Burford Capital Limited

Elizabeth O'Connell, CFA, Chief Financial Officer

+1 212 235 6825

Macquarie Capital (Europe) Limited - NOMAD and Joint Broker

+44 (0)20 3037 2000

Jonny Allison

Nicholas Harland

Liberum Capital Limited - Joint Broker

+44 (0)20 3100 2222

Richard Crawley

Jamie Richards

Numis Securities Limited - Joint Broker

+44 (0)20 7260 1000

Charlie Farquhar

Jonathan Abbott

Neustria Partners - Financial Communications for Burford Capital

+44 (0)20 3021 2580

Robert Bailhache - email

Charles Gorman - email

Nick Henderson - email

 

 

About Burford Capital

Burford Capital is the leading global finance and investment management firm focused on law. Its businesses include litigation finance and risk management, asset recovery and a wide range of legal finance and advisory activities. Burford is publicly traded on the London Stock Exchange, and it works with law firms and clients around the world from its principal offices in New York, London, Chicago and Singapore.

 

For more information about Burford: www.burfordcapital.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBBLLFVDFZBBB
Date   Source Headline
13th May 202412:00 pmRNS1Q24 Results & Quarterly Report
9th May 20247:00 amRNSNotice of 1Q24 Results & Results Call Details
16th Apr 20243:30 pmRNSHolding(s) in Company
10th Apr 202412:00 pmRNSNotice of Retail Shareholder Call on June 20, 2024
10th Apr 202412:00 pmRNSIssuance of New Shares in Connection With LTIP
10th Apr 202412:00 pmRNSNotice of 2024 AGM
3rd Apr 20244:30 pmRNSDirector/PDMR Shareholdings & Ownership Update
28th Mar 202411:00 amRNSAvailability of 2023 Annual Report
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20244:45 pmRNSNotification of Transactions by PDMRs
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20244:00 pmRNSIntended Purchases of Ordinary Shares
14th Mar 202411:00 amRNSAnnual results for year ended December 31, 2023
7th Mar 20245:30 pmRNSHolding(s) in Company
7th Mar 20242:00 pmRNSNotice of 2023 Results & Results Call Details
30th Jan 20244:15 pmRNSClosing of Private Offering of Senior Notes
18th Jan 202412:00 pmRNSPamela Corrie Appointed as Board Director
17th Jan 20247:00 amRNSPricing and Upsizing of Senior Notes Offering
16th Jan 202412:45 pmRNSPrivate Offering of Senior Notes
3rd Jan 202412:00 pmRNSIssuance of New Shares in Connection with LTIP
22nd Nov 202312:00 pmRNSDirector/PDMR Shareholding
16th Nov 202312:00 pmRNSSterling Conversion Rate for 2023 Interim Dividend
9th Nov 202312:00 pmRNS3Q23 Results & Quarterly Report
3rd Nov 20237:05 amRNSNotice of 3Q23 Results & Results Call Details
9th Oct 202312:00 pmRNSIssuance of New Shares in Connection with LTIP
9th Oct 202311:45 amRNSExpansion and Further Extension of SWF Arrangement
27th Sep 20235:30 pmRNSDirector/PDMR Shareholding
27th Sep 20237:00 amRNSTransaction in Own Shares
26th Sep 20237:00 amRNSTransaction in Own Shares
25th Sep 20237:00 amRNSTransaction in Own Shares
22nd Sep 20237:00 amRNSTransaction in Own Shares
21st Sep 20237:00 amRNSTransaction in Own Shares
19th Sep 20231:30 pmRNSTransaction in Own Shares
13th Sep 202312:00 pmRNS2Q23 Results & Quarterly Report
11th Sep 20237:00 amRNSStatement on YPF Damages Ruling
8th Sep 20234:30 pmRNSSuspension - Burford Capital Limited
8th Sep 20234:09 pmRNSStatement re Petersen and Eton Park Matters
31st Aug 20232:00 pmRNSNotice of 2Q23 Results Call Details
25th Aug 20237:00 amRNSUS SEC Closes Comment Letter Review
9th Aug 20232:00 pmRNSDirector/PDMR Shareholding
12th Jul 202310:37 amRNSResult of AGM
7th Jul 202312:45 pmRNSPricing of Early Redemption of 2024 Bonds
4th Jul 20235:00 pmRNSTransaction in Own Shares
3rd Jul 20232:00 pmRNSCompletion of Share Purchases & PDMR Transactions
29th Jun 202311:14 amRNSIntended Purchases of Ordinary Shares
26th Jun 20236:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.